PubRank

T Seufferlein

Author PubWeight™ 41.96‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Connections between single-cell biomechanics and human disease states: gastrointestinal cancer and malaria. Acta Biomater 2005 4.22
2 Transforming growth factor beta1 treatment leads to an epithelial-mesenchymal transdifferentiation of pancreatic cancer cells requiring extracellular signal-regulated kinase 2 activation. Cancer Res 2001 2.29
3 Insulin-like growth factor-I is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells. Cancer Res 2000 1.90
4 [Update S3-guideline "colorectal cancer" 2008]. Z Gastroenterol 2008 1.81
5 Molecular cloning and characterization of the human protein kinase D2. A novel member of the protein kinase D family of serine threonine kinases. J Biol Chem 2000 1.76
6 [German S3-guideline "Diagnosis and treatment of esophagogastric cancer"]. Z Gastroenterol 2011 1.74
7 Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann Oncol 2005 1.71
8 Regulation of cell growth and cyclin D1 expression by the constitutively active FRAP-p70s6K pathway in human pancreatic cancer cells. Cancer Res 1999 1.67
9 [S3-Guidelines "Exocrine pancreatic cancer" 2007]. Z Gastroenterol 2007 1.52
10 CD147 silencing inhibits lactate transport and reduces malignant potential of pancreatic cancer cells in in vivo and in vitro models. Gut 2009 1.31
11 Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study. Ann Oncol 2010 1.27
12 S3 guidelines for colorectal carcinoma: results of an evidence-based consensus conference on February 6/7, 2004 and June 8/9, 2007 (for the topics IV, VI and VII). Z Gastroenterol 2010 1.20
13 Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group. Ann Oncol 2008 1.02
14 Epidermal growth factor induces cyclin D1 in human pancreatic carcinoma: evidence for a cyclin D1-dependent cell cycle progression. Pancreas 2001 0.94
15 Adrenomedullin stimulates DNA synthesis and cell proliferation via elevation of cAMP in Swiss 3T3 cells. FEBS Lett 1996 0.94
16 Thirty-eight-negative kinase 1 (TNK1) facilitates TNFalpha-induced apoptosis by blocking NF-kappaB activation. Oncogene 2007 0.93
17 KOC is a novel molecular indicator of malignancy. Br J Cancer 2003 0.93
18 Substrate stiffness and the receptor-type tyrosine-protein phosphatase alpha regulate spreading of colon cancer cells through cytoskeletal contractility. Oncogene 2010 0.92
19 A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol 2009 0.90
20 Comparison of balloon vs. straight catheter for the measurement of portal hypertension. Aliment Pharmacol Ther 2010 0.85
21 Rapamycin dissociates p70(S6K) activation from DNA synthesis stimulated by bombesin and insulin in Swiss 3T3 cells. J Biol Chem 1997 0.84
22 Pharmacogenetic predictors for EGFR-inhibitor-associated skin toxicity. Pharmacogenomics J 2011 0.84
23 Lysophosphatidic acid-depleted serum, hepatocyte growth factor and stem cell growth factor stimulate colony growth of small cell lung cancer cells through a calcium-independent pathway. Cancer Res 1994 0.82
24 Subclinical ascites defines an intermediate stage between compensated and decompensated cirrhosis. Z Gastroenterol 2012 0.82
25 Microglial activation in multiple system atrophy: a potential role for NF-kappaB/rel proteins. Neuroreport 1998 0.82
26 Interleukin 1beta-converting enzyme (caspase-1) is overexpressed in adenocarcinoma of the pancreas. Cancer Res 1998 0.80
27 Effect of galanin on gastrin and somatostatin release from the rat stomach. Life Sci 1988 0.80
28 Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205. Br J Cancer 2013 0.80
29 [Antibiotic treatment of enterococcal infections in gastroenterology with daptomycin - first experiences from the EU-CORE registry study (European Cubicin® Outcomes Registry and Experience)]. Z Gastroenterol 2012 0.78
30 [Carcinoma of the pancreas: summary of guidelines 2007, issued jointly by 15 German specialist medical societies]. Dtsch Med Wochenschr 2007 0.78
31 [Chemotherapy for colorectal carcinoma in the elderly]. Z Gastroenterol 2004 0.78
32 [Immunosuppressive treatment as a risk factor for the occurrence of clostridium difficile infection (CDI)]. Z Gastroenterol 2013 0.78
33 Documented quality of care in certified colorectal cancer centers in Germany: German Cancer Society benchmarking report for 2013. Int J Colorectal Dis 2014 0.77
34 [Prolonged course of tick-borne ulceroglandular tularemia in a 20-year-old patient in Germany--case report and review of the literature]. Dtsch Med Wochenschr 2009 0.76
35 In-vivo monitoring of acute DSS-Colitis using Colonoscopy, high resolution Ultrasound and bench-top Magnetic Resonance Imaging in Mice. Eur Radiol 2015 0.76
36 Effect of gastrin-releasing peptide (GRP1-27), neuromedin-C (GRP18-27), and neuromedin-B on gastrin and somatostatin secretion from the rat stomach. Z Gastroenterol 1989 0.75
37 [Induced pluripotent stem cells. A new resource in modern medicine]. Internist (Berl) 2014 0.75
38 [Pregnancy and inflammatory bowel disease]. Internist (Berl) 2011 0.75
39 [What can colorectal cancer centers achieve in the diagnostics and therapy of colorectal liver metastases?]. Chirurg 2014 0.75
40 [ASCO-Update 2005--Highlights of the 41st Meeting of the American Society of Clinical Oncology/ASCO 2005]. Z Gastroenterol 2005 0.75
41 [Mechanisms of disease]. Z Gastroenterol 2005 0.75
42 [Certified stomach cancer centres as seen by their directors: results of a questionaire to key personnel]. Z Gastroenterol 2012 0.75
43 [ASCO update 2006--highlights of the 42. meeting of the American Society of Clinical Oncology/ASCO 2006]. Z Gastroenterol 2006 0.75
44 Atherosclerosis, aortic stenosis and sudden onset central diabetes insipidus. Exp Clin Endocrinol Diabetes 1997 0.75
45 [Pregnancy under immunosuppression]. Internist (Berl) 2011 0.75
46 [Personalized tumor therapy for gastrointestinal tumors]. Internist (Berl) 2015 0.75
47 [ASCO Update 2003 - Highlights of the 39th Meeting of the American Society of Clinical Oncology/ASCO 2003]. Z Gastroenterol 2003 0.75
48 [50 years for the ZfG]. Z Gastroenterol 2013 0.75
49 [Personalized therapy of gastrointestinal cancers--possibilities and limitations]. Dtsch Med Wochenschr 2010 0.75
50 [Adjuvant chemotherapy of solid tumors of the gastrointestinal tract: where is the progress?]. Internist (Berl) 2007 0.75
51 [ASCO update -- highlights of the 40th Meeting of the American Society of Clinical Oncology/ASCO 2004]. Z Gastroenterol 2004 0.75
52 Integrin-mediated differentiation of a pancreatic carcinoma cell line is independent of FAK or MAPK activation levels. Pancreas 2001 0.75
53 Evidence for radiosensitizing by gliotoxin in HL-60 cells: implications for a role of NF-kappaB independent mechanisms. Oncogene 2003 0.75
54 [Gastrointestinal oncology - therapy update 2008 / 2009]. Z Gastroenterol 2009 0.75
55 [Editorial]. Z Gastroenterol 2011 0.75
56 Effect of met-enkephalin and met-enkephalin-Arg6-Phe7 on bombesin-like immunoreactivity (BLI), somatostatin and gastrin secretion from the perfused rat stomach. Hepatogastroenterology 1990 0.75
57 [A 40-year-old female patient with seronegative autoimmune hepatitis following a newly acquired hepatitis B infection]. Z Gastroenterol 2008 0.75